- $34.87m
- -$145.60m
- $31.37m
EyePoint set for record drop after experimental eye drug misses late-stage study goal
EyePoint tumbles after experimental eye drug misses main goal in late-stage study
NASDAQ RESUMED AT 07:42 AM
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank (updated)
EyePoint eye drug misses main goal in late-stage trial
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: EyePoint Reports Inducement Grants Under Nasdaq Listing Rule
EyePoint Inc reports results for the quarter ended June 30 - Earnings Summary
EyePoint Pharmaceuticals Q2 revenue drops on lower license income
Brief: Eyepoint Enters Settlement Agreement With DOJ, OIG-HHS, And DHA - SEC Filing
EyePoint's late-stage eye drug trials to continue after safety panel review (updated)
EyePoint's late-stage eye drug trials to continue after safety panel review
Brief: Eyepoint Announces Third Consecutive Positive Dsmc Recommendation For Phase 3 Wet AMD Trials For Duravyu™, Building Confidence Ahead Of Mid-2026 Topline Data
EyePoint Pharmaceuticals Q1 net loss widens on increased R&D spending
Brief: Eyepoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug (updated)
Brief: Eyepoint Files Complaint Against Ocular Therapeutix In Middlesex County Superior Court
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug